{"commentary":{"count":44,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":26,"podcast":12,"x_thread":4,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05519085\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SUCCESSOR-1","nct_id":"NCT05519085","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=successor-1-nct05519085. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SUCCESSOR-1","arms":[{"description":null,"label":"MeziVd (mezigdomide, bortezomib and dexamethasone)","type":"EXPERIMENTAL"},{"description":null,"label":"PVd (pomalidomide, bortezomib and dexamethasone)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2033-11-30","type":"ESTIMATED"},"conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":{"count":810,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"mezigdomide","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"Celgene","official_title":"A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)"}],"references":[],"start_date":{"date":"2022-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","url":"https://clinicaltrials.gov/study/NCT05519085"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/successor-1-nct05519085"}